EUVIMEDEUVIMED entdecken
Multizentrische Studie

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

Clément Garnier, Martin Schein, Clémence Lacroix iD, Elisabeth Jouve iD, Thomas Soeiro iD, Gaétan Gentile, Maryse Lapeyre Mestre iD, Joëlle Micallef iD

CNS Drugs · 2024

DOI: 10.1007/s40263-024-01095-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CNS Drugs, 2024. Verfasst von Clément Garnier und 7 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacologie Clinique et Pharmacosurveillance, Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance Aix Mars…. Hauptthemen laut MEDLINE: Pregabalin, Substance-Related Disorders, Substance Abuse Treatment Centers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: In recent years, pregabalin has received growing attention due to its abuse liability. The aim of this study was to further characterize patterns of pregabalin users from substance abuse treatment facilities and detect changes in users profile over the study period. METHODS: The data source was the Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse (OPPIDUM) program, an annual, repeated, cross-sectional, nationwide, multicenter survey that collects consumption data from patients with substance use disorders. First, we described the characteristics of pregabalin users and their consumption patterns. We compared these data between 2008 and 2018 (P1) and 2019 and 2022 (P2). Second, we conducted a multiple correspondence analysis to identify profiles of users. RESULTS: From 2008 to 2022, 291 pregabalin users (0.37% of all users) from 116 substance abuse treatment facilities were identified. The number of pregabalin users was lower than 15 per year in P1 (n = 89) and between 40 and 60 per year in P2 (n = 202). The number of users who reported pregabalin as the first substance leading to dependence increased significantly in P2 compared with P1 (p 45 years), were involved in opioid agonist treatment (OAT), and obtained pregabalin legally; and (ii) a cluster with mainly users from P2, who presented pregabalin dependence, and were younger (< 26 years), reported pregabalin as the first substance leading to dependence, used doses higher than the market authorization, were in severe precarity, and were in prison. CONCLUSIONS: These data showed that the profile of pregabalin users has changed in the last years. Pregabalin use disorders also affect users without history of addiction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PregabalinSubstance-Related DisordersSubstance Abuse Treatment CentersHumansMaleFemaleAdultCross-Sectional StudiesFranceMiddle AgedYoung AdultAdolescent

Substanzen

Pregabalin

Autor:innen und Institutionen

  • Service de Pharmacologie Clinique et Pharmacosurveillance, Centre d'évaluation et d'information sur la pharmacodépendance - Addictovigilance Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, UMR 1106, University Hos…
  • Département Universitaire de Médecine Générale, Faculté des Sciences Médicales et paramédicales, Marseille, France.
  • Service de Pharmacologie Médicale et Clinique, UFR Santé Université de Toulouse - Paul Sabatier, CEIP-Addictovigilance de Toulouse, CHU de Toulouse, CIC 1436, 31000, Toulouse, France.

ORCID-Profile: Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Maryse Lapeyre Mestre, Joëlle Micallef

Zitieren

APA

Garnier, C., Schein, M., Lacroix, C., Jouve, E., Soeiro, T., Gentile, G., Lapeyre Mestre, M., & Micallef, J. (2024). Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS Drugs. https://doi.org/10.1007/s40263-024-01095-y

Vancouver

Garnier C, Schein M, Lacroix C, Jouve E, Soeiro T, Gentile G, et al. Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022. CNS Drugs. 2024. doi:10.1007/s40263-024-01095-y

BibTeX
@article{Garnier2024,
  author = {Garnier, Clément and Schein, Martin and Lacroix, Clémence and Jouve, Elisabeth and Soeiro, Thomas and Gentile, Gaétan and Lapeyre Mestre, Maryse and Micallef, Joëlle},
  title = {Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022},
  journal = {CNS Drugs},
  year = {2024},
  doi = {10.1007/s40263-024-01095-y}
}
Kostenlos starten →